# Teladoc Health, Inc.: financial statements, quarterly

TDOC · NYSE · CIK 1477449 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tdoc.md) · [Financials](/companies/tdoc/financials.md) · [Filings](/companies/tdoc/filings.md) · [Insiders](/companies/tdoc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tdoc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [660](/filings/0001477449-24-000225.md) | [661 d](/filings/0001477449-26-000012.md) | [646](/filings/0001477449-25-000049.md) | [642](/filings/0001477449-25-000099.md) | [641](/filings/0001477449-25-000120.md) | [640 d](/filings/0001477449-26-000012.md) | [629](/filings/0001477449-26-000028.md) | [632](/filings/0001477449-26-000038.md) | [626](/filings/0001477449-25-000120.md) | [642 d](/filings/0001477449-26-000012.md) | [614](/filings/0001477449-26-000028.md) | [607](/filings/0001477449-26-000038.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [84.3](/filings/0001477449-24-000225.md) | [89.9 d](/filings/0001477449-26-000012.md) | [81.4](/filings/0001477449-25-000049.md) | [76.8](/filings/0001477449-25-000099.md) | [72.4](/filings/0001477449-25-000120.md) | [76.8 d](/filings/0001477449-26-000012.md) | [70.0](/filings/0001477449-26-000028.md) | [68.8](/filings/0001477449-26-000038.md) | [67.6](/filings/0001477449-25-000120.md) | [71.6 d](/filings/0001477449-26-000012.md) | [67.9](/filings/0001477449-26-000028.md) | [62.9](/filings/0001477449-26-000038.md) |
| Operating income | $m | [(64.7)](/filings/0001477449-24-000225.md) | [(35.1) d](/filings/0001477449-26-000012.md) | [(87.1)](/filings/0001477449-25-000049.md) | [(841)](/filings/0001477449-25-000099.md) | [(44.4)](/filings/0001477449-25-000120.md) | [(48.2) d](/filings/0001477449-26-000012.md) | [(121)](/filings/0001477449-26-000028.md) | [(54.4)](/filings/0001477449-26-000038.md) | [(52.0)](/filings/0001477449-25-000120.md) | [(36.0) d](/filings/0001477449-26-000012.md) | [(61.8)](/filings/0001477449-26-000028.md) | [(37.1)](/filings/0001477449-26-000038.md) |
| Interest expense | $m | [5.6](/filings/0001477449-24-000225.md) | [5.5 d](/filings/0001477449-25-000005.md) | [5.6](/filings/0001477449-25-000049.md) | [5.6](/filings/0001477449-24-000174.md) | [5.7](/filings/0001477449-24-000225.md) | [6.8 d](/filings/0001477449-25-000005.md) | [5.8](/filings/0001477449-25-000049.md) | [4.5](/filings/0001477449-26-000038.md) | [4.5](/filings/0001477449-25-000120.md) | [5.0 d](/filings/0001477449-26-000012.md) | [5.4](/filings/0001477449-26-000028.md) | [5.1](/filings/0001477449-26-000038.md) |
| Income tax | $m | [(2.5)](/filings/0001477449-24-000225.md) | [3.5 d](/filings/0001477449-26-000012.md) | [2.7](/filings/0001477449-25-000049.md) | [3.9](/filings/0001477449-25-000099.md) | [0.8](/filings/0001477449-25-000120.md) | [0.2 d](/filings/0001477449-26-000012.md) | [(18.3)](/filings/0001477449-26-000028.md) | [(7.8)](/filings/0001477449-26-000038.md) | [(0.7)](/filings/0001477449-25-000120.md) | [(8.5) d](/filings/0001477449-26-000012.md) | [3.0](/filings/0001477449-26-000028.md) | [1.0](/filings/0001477449-26-000038.md) |
| Net income | $m | [(57.1)](/filings/0001477449-24-000225.md) | [(28.9) d](/filings/0001477449-26-000012.md) | [(81.9)](/filings/0001477449-25-000049.md) | [(838)](/filings/0001477449-25-000099.md) | [(33.3)](/filings/0001477449-25-000120.md) | [(48.4) d](/filings/0001477449-26-000012.md) | [(93.0)](/filings/0001477449-26-000028.md) | [(32.7)](/filings/0001477449-26-000038.md) | [(49.5)](/filings/0001477449-25-000120.md) | [(25.1) d](/filings/0001477449-26-000012.md) | [(63.8)](/filings/0001477449-26-000028.md) | [(38.9)](/filings/0001477449-26-000038.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001477449-24-000225.md) | not reported | [(0.49)](/filings/0001477449-25-000049.md) | [(4.92)](/filings/0001477449-25-000099.md) | [(0.19)](/filings/0001477449-25-000120.md) | not reported | [(0.53)](/filings/0001477449-26-000028.md) | [(0.19)](/filings/0001477449-26-000038.md) | [(0.28)](/filings/0001477449-25-000120.md) | not reported | [(0.36)](/filings/0001477449-26-000028.md) | [(0.21)](/filings/0001477449-26-000038.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0001477449-24-000225.md) | not reported | [(0.49)](/filings/0001477449-25-000049.md) | [(4.92)](/filings/0001477449-25-000099.md) | [(0.19)](/filings/0001477449-25-000120.md) | not reported | [(0.53)](/filings/0001477449-26-000028.md) | [(0.19)](/filings/0001477449-26-000038.md) | [(0.28)](/filings/0001477449-25-000120.md) | not reported | [(0.36)](/filings/0001477449-26-000028.md) | [(0.21)](/filings/0001477449-26-000038.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,031](/filings/0001477449-23-000066.md) | [1,124](/filings/0001477449-25-000005.md) | [1,098](/filings/0001477449-24-000101.md) | [1,162](/filings/0001477449-24-000174.md) | [1,244](/filings/0001477449-24-000225.md) | [1,298](/filings/0001477449-26-000012.md) | [1,193](/filings/0001477449-25-000049.md) | [680](/filings/0001477449-25-000099.md) | [726](/filings/0001477449-25-000120.md) | [781](/filings/0001477449-26-000038.md) | [751](/filings/0001477449-26-000028.md) | [774](/filings/0001477449-26-000038.md) |
| Current assets | $m | [1,387](/filings/0001477449-23-000066.md) | [1,489](/filings/0001477449-25-000005.md) | [1,486](/filings/0001477449-24-000101.md) | [1,547](/filings/0001477449-24-000174.md) | [1,609](/filings/0001477449-24-000225.md) | [1,664](/filings/0001477449-26-000012.md) | [1,602](/filings/0001477449-25-000049.md) | [1,073](/filings/0001477449-25-000099.md) | [1,093](/filings/0001477449-25-000120.md) | [1,119](/filings/0001477449-26-000038.md) | [1,132](/filings/0001477449-26-000028.md) | [1,148](/filings/0001477449-26-000038.md) |
| Total assets | $m | [4,328](/filings/0001477449-23-000066.md) | [4,392](/filings/0001477449-25-000005.md) | [4,321](/filings/0001477449-24-000101.md) | [3,524](/filings/0001477449-24-000174.md) | [3,529](/filings/0001477449-24-000225.md) | [3,517](/filings/0001477449-26-000012.md) | [3,444](/filings/0001477449-25-000049.md) | [2,894](/filings/0001477449-25-000099.md) | [2,879](/filings/0001477449-25-000120.md) | [2,858](/filings/0001477449-26-000038.md) | [2,807](/filings/0001477449-26-000028.md) | [2,759](/filings/0001477449-26-000038.md) |
| Current liabilities | $m | [403](/filings/0001477449-23-000066.md) | [421](/filings/0001477449-25-000005.md) | [389](/filings/0001477449-24-000101.md) | [931](/filings/0001477449-24-000174.md) | [931](/filings/0001477449-24-000225.md) | [942](/filings/0001477449-26-000012.md) | [952](/filings/0001477449-25-000049.md) | [402](/filings/0001477449-25-000099.md) | [405](/filings/0001477449-25-000120.md) | [405](/filings/0001477449-26-000038.md) | [405](/filings/0001477449-26-000028.md) | [1,382](/filings/0001477449-26-000038.md) |
| Total liabilities | $m | not reported | [2,066](/filings/0001477449-25-000005.md) | not reported | [2,022](/filings/0001477449-24-000174.md) | [2,021](/filings/0001477449-24-000225.md) | [2,025](/filings/0001477449-26-000012.md) | [2,017](/filings/0001477449-25-000049.md) | [1,472](/filings/0001477449-25-000099.md) | [1,486](/filings/0001477449-25-000120.md) | [1,473](/filings/0001477449-26-000038.md) | [1,471](/filings/0001477449-26-000028.md) | [1,449](/filings/0001477449-26-000038.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,294](/filings/0001477449-24-000225.md) | [2,326](/filings/0001477449-26-000012.md) | [2,289](/filings/0001477449-25-000099.md) | [1,502](/filings/0001477449-25-000120.md) | [1,508](/filings/0001477449-25-000120.md) | [1,491](/filings/0001477449-26-000038.md) | [1,427](/filings/0001477449-26-000038.md) | [1,422](/filings/0001477449-26-000038.md) | [1,392](/filings/0001477449-25-000120.md) | [1,386](/filings/0001477449-26-000038.md) | [1,336](/filings/0001477449-26-000038.md) | [1,310](/filings/0001477449-26-000038.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [106 d](/filings/0001477449-24-000225.md) | [130 d](/filings/0001477449-26-000012.md) | [8.9](/filings/0001477449-25-000049.md) | [88.7 d](/filings/0001477449-25-000099.md) | [110 d](/filings/0001477449-25-000120.md) | [85.9 d](/filings/0001477449-26-000012.md) | [15.9](/filings/0001477449-26-000028.md) | [91.4 d](/filings/0001477449-26-000038.md) | [99.3 d](/filings/0001477449-25-000120.md) | [87.7 d](/filings/0001477449-26-000012.md) | [9.5](/filings/0001477449-26-000028.md) | [64.7 d](/filings/0001477449-26-000038.md) |
| Capital expenditure | $m | [5.8 d](/filings/0001477449-24-000225.md) | [1.4 d](/filings/0001477449-26-000012.md) | [1.1](/filings/0001477449-25-000049.md) | [1.9 d](/filings/0001477449-25-000099.md) | [1.6 d](/filings/0001477449-25-000120.md) | [6.1 d](/filings/0001477449-26-000012.md) | [2.7](/filings/0001477449-26-000028.md) | [1.3 d](/filings/0001477449-26-000038.md) | [2.3 d](/filings/0001477449-25-000120.md) | [2.6 d](/filings/0001477449-26-000012.md) | [1.7](/filings/0001477449-26-000028.md) | [0.9 d](/filings/0001477449-26-000038.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [162](/filings/0001477449-23-000066.md) | [163](/filings/0001477449-24-000101.md) | [164](/filings/0001477449-24-000174.md) | [165](/filings/0001477449-24-000225.md) | [168](/filings/0001477449-25-000049.md) | [170](/filings/0001477449-25-000099.md) | [171](/filings/0001477449-25-000120.md) | [174](/filings/0001477449-26-000028.md) | [176](/filings/0001477449-26-000038.md) | [177](/filings/0001477449-25-000120.md) | [179](/filings/0001477449-26-000028.md) | [181](/filings/0001477449-26-000038.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 181,684,021 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001477449-26-000038.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.